Literature DB >> 16125792

Fc receptors and their interaction with complement in autoimmunity.

Reinhold E Schmidt1, J Engelbert Gessner.   

Abstract

Genetic studies in mice indicate a crucial role for Fc receptors (FcR) in antibody-mediated autoimmune diseases. Like other immune regulatory receptor pairs, the FcR system is constituted by activating and inhibitory receptors that bind the same ligand, the Fc portion of Ig. Analyses of animal models have shown that the inhibitory Fc receptor, FcgammaRIIB can suppress antibody-mediated autoimmunity, whereas activating-type FcR, such as FcgammaRIII promote disease development. This review summarizes recent advances of FcR, as obtained from gene deletion studies in mice, and highlights the importance of factors that interact with FcR in autoimmunity. There is emerging evidence for an indispensable role of the complement component C5a in the regulation of FcR and the sensing of FcR-dependent effector cell responses. On the other hand, FcR might be alternatives to serum complement in the generation of C5a at sites of inflammation. Thus, FcR and complement interact with each other at the level of C5a by linking regulatory events with effector cell activities in autoimmunity. This connecting pathway is now proposed to be a promising new therapeutic target for the treatment of inflammation and autoimmune disease in both mice and humans.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16125792     DOI: 10.1016/j.imlet.2005.06.022

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  59 in total

Review 1.  Activating and inhibitory FcgammaRs in autoimmune disorders.

Authors:  Falk Nimmerjahn
Journal:  Springer Semin Immunopathol       Date:  2006-10-01

2.  NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement.

Authors:  Siao-Yi Wang; Emilian Racila; Ronald P Taylor; George J Weiner
Journal:  Blood       Date:  2007-11-16       Impact factor: 22.113

3.  Effect of complement and its regulation on myasthenia gravis pathogenesis.

Authors:  Linda L Kusner; Henry J Kaminski; Jindrich Soltys
Journal:  Expert Rev Clin Immunol       Date:  2008-01       Impact factor: 4.473

Review 4.  Complement System: a Neglected Pathway in Immunotherapy.

Authors:  Anne Bordron; Cristina Bagacean; Adrian Tempescul; Christian Berthou; Eléonore Bettacchioli; Sophie Hillion; Yves Renaudineau
Journal:  Clin Rev Allergy Immunol       Date:  2020-04       Impact factor: 8.667

Review 5.  [Fcγ receptors].

Authors:  J E Gessner; R E Schmidt
Journal:  Z Rheumatol       Date:  2013-02       Impact factor: 1.372

6.  Aglycosylated IgG variants expressed in bacteria that selectively bind FcgammaRI potentiate tumor cell killing by monocyte-dendritic cells.

Authors:  Sang Taek Jung; Sai T Reddy; Tae Hyun Kang; M Jack Borrok; Inger Sandlie; Philip W Tucker; George Georgiou
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-18       Impact factor: 11.205

Review 7.  Differential antibody glycosylation in autoimmunity: sweet biomarker or modulator of disease activity?

Authors:  Michaela Seeling; Christin Brückner; Falk Nimmerjahn
Journal:  Nat Rev Rheumatol       Date:  2017-09-14       Impact factor: 20.543

Review 8.  Immunoglobulin G: a potential treatment to attenuate neuroinflammation following spinal cord injury.

Authors:  Michael G Fehlings; Dung H Nguyen
Journal:  J Clin Immunol       Date:  2010-05       Impact factor: 8.317

9.  Malaria inhibits surface expression of complement receptor 1 in monocytes/macrophages, causing decreased immune complex internalization.

Authors:  Cristina Fernandez-Arias; Jean Pierre Lopez; Jean Nikolae Hernandez-Perez; Maria Dolores Bautista-Ojeda; Oralee Branch; Ana Rodriguez
Journal:  J Immunol       Date:  2013-02-25       Impact factor: 5.422

Review 10.  The regulatory power of glycans and their binding partners in immunity.

Authors:  Jenny L Johnson; Mark B Jones; Sean O Ryan; Brian A Cobb
Journal:  Trends Immunol       Date:  2013-02-26       Impact factor: 16.687

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.